UNSPSC 51384531: Naproxen etemesil

This classification denotes a cyclooxygenase inhibitor C17H20O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 214269U36R, chemically known as 2-naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-(methylsulfonyl)ethyl ester, (.alpha.s)-, but more generally known as naproxen etemesil, which bears US NIH Compound Identifier 25170420. Most nations, for tariff and trade purposes, schedule naproxen etemesil under HS 29189900 and SITC 51396. As of Q4 2014, NAPROXEN ETEMESIL remains US FDA's Preferred Term for this commodity.

SMILES: C[C@@H](C1CCC2CC(CCC2C1)OC)C(=O)OCCS(=O)(=O)C.

UNSPSC 51384531 Naproxen etemesil is a Commodity code that nominally specifies a single anti-inflammatory drug product, but recent state and local procurement activity shows the code is being applied to broader pharmaceutical procurement — including naloxone, safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. State and local buyers soliciting under or near this code include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, including Oregon). The solicitations reflect two distinct purchasing patterns: direct procurement of specific pharmaceutical products for community health and emergency response, and cooperative purchasing frameworks that establish supply relationships with multiple manufacturers through authorized wholesalers to serve statewide and multi-state networks.

Recent activity spans Florida, Texas, and the Upper Midwest. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program, signaling exploratory procurement before formal RFP release. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products distributed across participating state and local facilities, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. MMCAP requires vendors to partner with authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), comply with cGMP and Drug Supply Chain Security Act standards, and accept a 3 percent administrative fee. The code sees activity driven by state health departments managing benefit programs and emergency response, not individual practitioners or retail pharmacy.